Data Available

The following data have been deposited at the European Genotyping Archive:

• Gambia Case-Control (Affymetrix 500K platform)
• Gambia, Ghana, Malawi trios (Illumina 650Y platform)

Gambian Case Control Study of Severe Malaria

• a pilot study as part of Consortial Project 1
• 1059 samples from cases of severe malaria
• 1496 cord blood control samples
• genotyped on Affymetrix 500k gene chip

For each of these samples, one set of genotypes - called by CHIAMO - is available, as discussed and used in the analysis by the Wellcome Trust Case Control Consortium (WTCCC).

Trio Datasets from Gambia, Ghana and Malawi

Data sets currently available from Consortial Project 1

• 658 Gambian families (1984 individuals)
  • 650 unique trios (3 individuals/family)
  • 6 quads (4 individuals/family)
  • 2 x ½ siblings (5 individuals/family)

• 608 Ghanaian trios (1824 individuals)

• 122 Malawian trios (366 individuals)

  Please note that this dataset has been prepared for release by MalariaGEN. The data will be released as soon as the relevant ethics committee confirms the range of acceptable research purposes for which it may be used.

All children have been diagnosed with malaria in a hospital.

All samples were genotyped on the Illumina 650Y array – genotypes were called using Illuminus.

This data release contains complete trios that have passed quality control (click here for a more detailed description of the files and data available for each sample set).

Use of MalariaGEN datasets

These datasets (excluding the Malawian trios) can be accessed for the following purposes:

• research into malaria and other specific diseases
• relevant methodological research and teaching - such as the development of biostatistical methods and applications for analysing and interpreting genome-wide data

The use of data for research purposes that are not directly relevant to health, such as anthropological research to understand the history of human populations, will be referred by the Independent Data Access Committee to the relevant research ethics committee on a case-by-case basis. In such cases the application should incorporate detailed information on the study hypothesis and the likely outcomes and conclusions, including any potential impact these may have on health.